09:13 AM EDT, 09/25/2025 (MT Newswires) -- (Updates with Eli Lilly's ( LLY ) response in the fifth paragraph)

Eli Lilly ( LLY ) has stopped its study evaluating the impact of bimagrumab and tirzepatide, alone or in combination, in lowering body weight in obesity patients with type 2 diabetes, an update from the US registry of clinical trials showed Wednesday.

The study was terminated for strategic business reasons, the website showed.

The phase 2 double-blind, randomized, placebo-controlled study, originally intended to last about 13 months, was active for less than a month between May 10 and June 6, according to study details from the website.

A similar study evaluating bimagrumab and tirzepatide, alone or in combination, in obesity patients without type 2 diabetes is still active and recruiting participants, the website showed.

"We routinely evaluate our clinical development programs to optimize the potential for each product," a spokesperson for Eli Lilly ( LLY ) said in an emailed statement to MT Newswires.